235 related articles for article (PubMed ID: 15151954)
1. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
Muro K; Hamaguchi T; Ohtsu A; Boku N; Chin K; Hyodo I; Fujita H; Takiyama W; Ohtsu T
Ann Oncol; 2004 Jun; 15(6):955-9. PubMed ID: 15151954
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.
Heath EI; Urba S; Marshall J; Piantadosi S; Forastiere AA
Invest New Drugs; 2002 Feb; 20(1):95-9. PubMed ID: 12003198
[TBL] [Abstract][Full Text] [Related]
4. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Kotsakis A; Matikas A; Koinis F; Kentepozidis N; Varthalitis II; Karavassilis V; Samantas E; Katsaounis P; Dermitzaki EK; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2016 Sep; 115(7):784-8. PubMed ID: 27607471
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
Guardiola E; Peyrade F; Chaigneau L; Cupissol D; Tchiknavorian X; Bompas E; Madroszyk A; Ronchin P; Schneider M; Bleuze JP; Blay JY; Pivot X
Eur J Cancer; 2004 Sep; 40(14):2071-6. PubMed ID: 15341981
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Perng RP; Shih JF; Chen YM; Chou KC; Lee YC; Tsai CM
Jpn J Clin Oncol; 2000 Oct; 30(10):429-34. PubMed ID: 11185888
[TBL] [Abstract][Full Text] [Related]
14. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
Govindan R; Read W; Faust J; Trinkaus K; Ma MK; Baker SD; McLeod HL; Perry MC
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):27-31. PubMed ID: 14569845
[TBL] [Abstract][Full Text] [Related]
16. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
19. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
Papakostas P; Kouroussis C; Androulakis N; Samelis G; Aravantinos G; Kalbakis K; Sarra E; Souglakos J; Kakolyris S; Georgoulias V
Eur J Cancer; 2001 Oct; 37(15):1833-8. PubMed ID: 11576836
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Tsai JY; Iannitti D; Berkenblit A; Akerman P; Nadeem A; Rathore R; Harrington D; Roye D; Miner T; Barnett JM; Maia C; Stuart K; Safran H
Am J Clin Oncol; 2005 Aug; 28(4):329-33. PubMed ID: 16062072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
